Absorption and metabolism of triclosan after application to the skin of B6C3F1 mice

Environmental Toxicology

Volumn 31, Issue 5, 2016, Pages 609-623

  Fang, Jia Long ^a   Vanlandingham, Michelle ^a   da Costa, Gonçalo Gamboa ^a   Beland, Frederick A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Dermal toxicity; Excretion; Metabolism; Tissue distribution; Toxicokinetics; Triclosan

Indexed keywords

ANTIMICROBIAL AGENTS; BIOMEDICAL EQUIPMENT; ETHANOL; HISTOLOGY; MAMMALS; METABOLISM; PHYSIOLOGY; RADIATION; RADIOACTIVITY; TISSUE; TOXICITY;

2 ,4-DICHLOROPHENOL; EXCRETION; METABOLITE PROFILES; PERSONAL CARE PRODUCTS; TISSUE DISTRIBUTIONS; TOPICAL APPLICATION; TOXICOKINETICS; TRICLOSAN;

TISSUE ENGINEERING;

2,4 DICHLOROPHENOL; ALCOHOL; COSMETIC; HYDROXYTRICLOSAN; PROPYLENE GLYCOL; TRICLOSAN; TRICLOSAN GLUCURONIDE; TRICLOSAN SULFATE; UNCLASSIFIED DRUG;

ABSORPTION; ANTIBIOTICS; CARCINOGEN; CONCENTRATION (COMPOSITION); EXCRETION; METABOLISM; PPCP; REACTION KINETICS; RODENT; SKIN; TRANSLOCATION;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; GALLBLADDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SKIN; ADSORPTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; FECES; MASS SPECTROMETRY; METABOLISM; RECEIVER OPERATING CHARACTERISTIC; REVERSED PHASE LIQUID CHROMATOGRAPHY; TISSUE DISTRIBUTION;

MUS;

ADSORPTION; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; FECES; FEMALE; MALE; MASS SPECTROMETRY; MICE; ROC CURVE; SKIN; TISSUE DISTRIBUTION; TRICLOSAN;

EID: 84962809854     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.22074     Document Type: Article

References (27)

1. Allmyr M, Adolfsson-Erici M, McLachlan MS, Sandborgh-Englund G. 2006. Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. Sci Total Environ 372:87-93.
2. Bagley DM, Lin YJ. 2000. Clinical evidence for the lack of triclosan accumulation from daily use in dentifrices. Am J Dent 13:148-152.
3. Bhargava HN, Leonard PA. 1996. Triclosan: Applications and safety. Am J Infect Control 24:209-218.
4. Black JG, Howes D. 1975. Percutaneous absorption of triclosan from toilet preparations. J Soc Cosmet Chem 26:205-215.
5. Black JG, Howes D, Rutherford T. 1975. Percutaneous absorption and metabolism of Irgasan DP300. Toxicology 3:33-47.
6. Burns JM, Moore MR, Dehler D, Arrington JF Jr, Ridder R, Thakur AK, Smyth M, Centanni NM, Palmer MF, Hassan A. 2001a. 14-Day repeated dose dermal study of triclosan in rats (CHV6718-102). FDA Docket 1975N-0183H, OTC Volume Number 118.
7. Burns JM, Moore MR, Dehler D, Arrington JF Jr, Ridgway R, Thakur AK, Smyth M, Centanni NM, Palmer MF, Hassan A. 2001b. 14-Day repeated dose dermal study of triclosan in CD-1 mice (CHV2763-100). FDA Docket 1975N-0183H, OTC Volume Number 120.
8. Burns JM, Moore MR, Dehler D, Arrington Jr. JF, Ridgway R, Thakur AK, Smyth M, Centanni NM, Palmer MF, Hassan A. 2001c. 14-Day repeated dose dermal study of triclosan in mice (CHV6718-101). FDA Docket 1975N-0183H, OTC Volume Number 119.
9. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. 2008. Urinary concentrations of triclosan in the U.S. population: 2003-2004. Environ. Health Perspect 116:303-307.
10. Dayan AD. 2007. Risk assessment of triclosan [Irgasan®] in human breast milk. Food Chem Toxicol 45:125-129.
11. DeSalva SJ, Kong BM, Lin YJ. 1989. Triclosan: A safety profile. Am J Dent 2:185-196.
12. Fang JL, Stingley RL, Beland FA, Harrouk W, Lumpkins DL, Howard P. 2010. Occurrence, efficacy, metabolism, and toxicity of triclosan. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 28:147-171.
13. Jones RD, Jampani HB, Newman JL, Lee AS. 2000. Triclosan: A review of effectiveness and safety in health care settings. Am J Infect Control 28:184-196.
14. Kanetoshi A, Ogawa H, Katsura E, Okui T, Kaneshima H. 1988. Disposition and excretion of Irgasan DP300 and its chlorinated derivatives in mice. Arch Environ Contam Toxicol 17:637-644.
15. Kanetoshi A, Katsura E, Ogawa H, Ohyama T, Kaneshima H, Miura T. 1992. Acute toxicity, percutaneous absorption and effects on hepatic mixed function oxidase activities of 2, 4, 4′-trichloro-2′-hydroxydiphenyl ether (Irgasan DP300) and its chlorinated derivatives. Arch Environ Contam Toxicol 23:91-98.
16. Lin YJ. 2000. Buccal absorption of triclosan following topical mouthrinse application. Am J Dent 13:215-217.
17. Loraine GA, Pettigrove ME. 2006. Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in southern California. Environ Sci Technol 40:687-695.
18. Lyman FL, Furia T. 1969. Toxicology of 2, 4, 4′-trichloro-2′-hydroxy-diphenyl ether. IMS Ind Med Surg 38:64-71.
19. Moss T, Howes D, Williams FM. 2000. Percutaneous penetration and dermal metabolism of triclosan (2, 4, 4′-trichloro-2′-hydroxydiphenyl ether). Food Chem Toxicol 38:361-370.
20. NTP. 2010. Photocarcinogenesis study of aloe vera [CAS NO. 481-72-1(Aloe-emodin)] in SKH-1 mice (simulated solar light and topical application study). Natl Toxicol Program Tech Rep Ser 553:1-210.
21. Queckenberg C, Meins J, Wachall B, Doroshyenko O, Tomalik-Scharte D, Bastian B, Abdel-Tawab M, Fuhr U. 2010. Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob Agents Chemother 54:570-572.
22. Rodricks JV, Swenberg JA, Borzelleca JF, Maronpot RR, Shipp AM. 2010. Triclosan: A critical review of the experimental data and development of margins of safety for consumer products. Crit Rev Toxicol 40:422-484.
23. Sandborgh-Englund G, Adolfsson-Erici M, Odham G, Ekstrand J. 2006. Pharmacokinetics of triclosan following oral ingestion in humans. J Toxicol Environ Health 69:1861-1873.
24. Siddiqui WH, Buttar HS. 1979. Pharmacokinetics of triclosan in rat after intravenous and intravaginal administration. J Environ Pathol Toxicol 2:861-871.
25. Singer H, Muller S, Tixier C, Pillonel L. 2002. Triclosan: Occurrence and fate of a widely used biocide in the aquatic environment: Field measurements in wastewater treatment plants, surface waters, and lake sediments. Environ Sci Technol 36:4998-5004.
26. Trimmer GW, Hostetler KA, Phillips RD, Forgash RC, Frank ER, Elliott MA, Lonardo EE, Letinski DJ, Stillman JE, Jackson JR, McGrath JL, Harris RL, Morris CF, Clinton JM 1994. 90-Day subchronic dermal toxicity study in the rat with satellite group with Irgasan DP300 (MRD-92-399). FDA Docket 1975N-0183H, OTC Volume Number 116.
27. Tulp MT, Sundstrom G, Martron LB, Hutzinger O. 1979. Metabolism of chlorodiphenyl ethers and Irgasan DP 300. Xenobiotica 9:65-77.